These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 36686189)

  • 1. The role of cannabinoids in pain modulation in companion animals.
    Miranda-Cortés A; Mota-Rojas D; Crosignani-Outeda N; Casas-Alvarado A; Martínez-Burnes J; Olmos-Hernández A; Mora-Medina P; Verduzco-Mendoza A; Hernández-Ávalos I
    Front Vet Sci; 2022; 9():1050884. PubMed ID: 36686189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
    Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
    CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabis and the exocannabinoid and endocannabinoid systems. Their use and controversies.
    Millán-Guerrero RO; Isais-Millán S
    Gac Med Mex; 2019; 155(5):471-474. PubMed ID: 32091020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging role of cannabinoids and synthetic cannabinoid receptor 1/cannabinoid receptor 2 receptor agonists in cancer treatment and chemotherapy-associated cancer management.
    Shah SA; Gupta AS; Kumar P
    J Cancer Res Ther; 2021; 17(1):1-9. PubMed ID: 33723124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antinociception mechanisms of action of cannabinoid-based medicine: an overview for anesthesiologists and pain physicians.
    Narouze S
    Reg Anesth Pain Med; 2021 Mar; 46(3):240-250. PubMed ID: 33239391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of cannabinoids in CNS disease.
    Croxford JL
    CNS Drugs; 2003; 17(3):179-202. PubMed ID: 12617697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
    Rosenberg EC; Patra PH; Whalley BJ
    Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
    Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
    Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabis and cannabinoids: pharmacology and rationale for clinical use.
    Pertwee RG
    Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral effects of cannabinoid agents in animals.
    Chaperon F; Thiébot MH
    Crit Rev Neurobiol; 1999; 13(3):243-81. PubMed ID: 10803637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in the expression of endocannabinoid system components in an experimental model of chemotherapy-induced peripheral neuropathic pain: Evaluation of sex-related differences.
    Noya-Riobó MV; Miguel CÁ; Soriano DB; Brumovsky PR; Villar MJ; Coronel MF
    Exp Neurol; 2023 Jan; 359():114232. PubMed ID: 36179876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cannabis y los sistemas exocannabinoide y endocannabinoide. Su uso y controversias.
    Millán-Guerrero RO; Isais-Millán S
    Gac Med Mex; 2019; 155(5):508-512. PubMed ID: 31695229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cannabinoid Receptor Type 1 and Its Role as an Analgesic: An Opioid Alternative?
    Milligan AL; Szabo-Pardi TA; Burton MD
    J Dual Diagn; 2020; 16(1):106-119. PubMed ID: 31596190
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses.
    Walsh KB; McKinney AE; Holmes AE
    Front Pharmacol; 2021; 12():777804. PubMed ID: 34916950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabis and Neuropsychiatric Disorders: An Updated Review.
    Chayasirisobhon S
    Acta Neurol Taiwan; 2019 Jun; 28(2)():27-39. PubMed ID: 31867704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabis and its constituents for cancer: History, biogenesis, chemistry and pharmacological activities.
    Lal S; Shekher A; Puneet ; Narula AS; Abrahamse H; Gupta SC
    Pharmacol Res; 2021 Jan; 163():105302. PubMed ID: 33246167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The neurobiology and evolution of cannabinoid signalling.
    Elphick MR; Egertová M
    Philos Trans R Soc Lond B Biol Sci; 2001 Mar; 356(1407):381-408. PubMed ID: 11316486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic potential of cannabinoids in schizophrenia.
    Kucerova J; Tabiova K; Drago F; Micale V
    Recent Pat CNS Drug Discov; 2014 Apr; 9(1):13-25. PubMed ID: 24605939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-CB1, non-CB2 receptors for endocannabinoids, plant cannabinoids, and synthetic cannabimimetics: focus on G-protein-coupled receptors and transient receptor potential channels.
    De Petrocellis L; Di Marzo V
    J Neuroimmune Pharmacol; 2010 Mar; 5(1):103-21. PubMed ID: 19847654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel phytocannabinoids from Ganoderma by label-free dynamic mass redistribution assay.
    Zhou H; Peng X; Hou T; Zhao N; Qiu M; Zhang X; Liang X
    J Ethnopharmacol; 2020 Jan; 246():112218. PubMed ID: 31494202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.